^
    7d
    INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas (clinicaltrials.gov)
    P1, N=13, Active, not recruiting, Pediatric Brain Tumor Consortium | Trial completion date: Jun 2024 --> Mar 2025
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD4 (CD4 Molecule) • ADAM10 (ADAM Metallopeptidase Domain 10)
    |
    aderbasib (INCB7839)
    over1year
    INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas (clinicaltrials.gov)
    P1, N=13, Active, not recruiting, Pediatric Brain Tumor Consortium | Recruiting --> Active, not recruiting | N=28 --> 13
    Enrollment closed • Enrollment change
    |
    CD4 (CD4 Molecule)
    |
    aderbasib (INCB7839)
    almost2years
    INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas (clinicaltrials.gov)
    P1, N=28, Recruiting, Pediatric Brain Tumor Consortium | Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    aderbasib (INCB7839)
    over2years
    Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer. (PubMed, J Exp Clin Cancer Res)
    Our study shows that CRC resistance to EGFR inhibitors results primarily from the inability of the inhibitors to downregulate their target and that a PEPD-based combination treatment overcomes the resistance.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • ADAM17 (ADAM Metallopeptidase Domain 17) • ADAM10 (ADAM Metallopeptidase Domain 10)
    |
    KRAS mutation • EGFR mutation • BRAF mutation • PIK3CA mutation • HER-2 mutation • EGFR overexpression • PIK3CA expression • PIK3CA overexpression • KRAS expression
    |
    Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • aderbasib (INCB7839)
    almost3years
    INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas (clinicaltrials.gov)
    P1, N=28, Recruiting, Pediatric Brain Tumor Consortium | Trial primary completion date: Mar 2022 --> Dec 2022
    Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    aderbasib (INCB7839)
    3years
    INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas (clinicaltrials.gov)
    P1, N=28, Recruiting, Pediatric Brain Tumor Consortium | Active, not recruiting --> Recruiting
    Clinical • Enrollment open
    |
    CD4 (CD4 Molecule)
    |
    aderbasib (INCB7839)